Fine-mapping of breast cancer GWAS regions has identified 195 high confidence signals containing more than 5,000 credible causal variants (CCVs). The CCVs are predominantly noncoding and enriched in regulatory elements and thus may confer the risk by altering gene expression in cis. We analyzed allelic expression imbalance (AEI) of genes surrounding known breast cancer signals, using normal breast and breast tumor transcriptome data and imputed genotypes. Fourteen genes, including NTN4, were identified whose expression was associated with CCV genotype. We showed that CCVs at this signal were located within an enhancer that physically interacts with the NTN4 promoter. Furthermore, knockdown of NTN4 in breast cells increased cell proliferation in vitro and tumor growth in vivo. Here, we present the most comprehensive AEI analysis of breast cancer CCVs resulting in identification of new candidate risk genes.
INTRODUCTION
The influence of common genetic variation on gene expression underlies a considerable proportion of the heritability associated with complex traits. Several studies indicate that the majority of traitassociated variants identified by Genome Wide Association Studies (GWAS) act by modulating gene expression in cis through altered distal and proximal regulatory elements 1 . Mapping of expression quantitative trait loci (eQTL), where genetic variants are tested for association with gene expression, is widely used to identify genes that are regulated by trait-associated variants. Several studies have shown that eQTLs are enriched in cell types relevant to the trait of interest 2, 3 . For example, T cellspecific eQTLs are over-represented for autoimmune risk alleles and monocyte-specific eQTLs for Alzheimer's and Parkinson's disease alleles 3 . These studies highlight the importance of using relevant tissue or cell types for functional studies.
An alternative method, allelic expression imbalance (AEI) analyses, can identify associations between an imbalance of allelic expression and trait-associated variants. An advantage of AEI analyses is that associations between gene expression and genotype can be detected using substantially fewer samples as AEI is measured within individuals, thereby controlling for cellular environment and trans-acting genetic factors. A handful of studies have performed AEI analyses to identify genes whose expression is associated with nearby GWAS variants. For example, we and others have identified associations between AEI and risk variants for breast cancer (ESR1, COX11
and HELQ) [4] [5] [6] , follicular lymphoma (HLA-DQB1) 7 and high-density lipoprotein-cholesterol levels (MMAB) 8 .
GWAS, together with fine-mapping, have identified 196 genetic signals (with conditional p-values<10 -6 ) associated with breast cancer risk 9 . However, identifying the credible causal variants (CCVs) driving the association and the genes affected by those variants is challenging. A recent study by Fachal et al has defined the CCVs as those with p-values within two orders of magnitude of the most significant CCV within the signal 9 . A signal at 17q21.31 containing 2277 CCVs cosegregates with a previously described large genomic rearrangement 10 . Following exclusion of the 17q21.31 signal, Fachal et al identified 5117 CCVs across 195 breast cancer risk signals. The majority of the CCVs fall within noncoding sequences and, in particular, they are enriched in genomic regions marked for regulatory activity suggesting that many of them may act by modulating gene expression in cis. In this study, we performed AEI analyses of genes surrounding the 195 breast cancer GWAS signals and identified 14 genes whose AEI was associated with CCVs (q-value<0.01).
For one gene, NTN4, we provide mechanistic insight into how breast cancer CCVs influence NTN4 expression, breast cancer cell proliferation and tumor development.
RESULTS

AEI analyses identified 14 candidate breast cancer risk genes
To identify new breast cancer risk genes whose expression is associated with breast cancer CCVs we used GTEx and TCGA breast samples with available RNA-seq and imputation data, including 81 GTEx normal, 46 TCGA normal, and 669 TCGA tumor samples. We were able to retrieve imputed genotypes for 4441 CCVs spanning over 190 signals. For each individual, from the genes within 1Mb up-and downstream of the CCVs, we selected those with at least one heterozygote transcribed single nucleotide polymorphism (htSNP), including 2195 and 2068 genes in the normal and tumor datasets, respectively. The major transcribed allele fraction (MTAF) representing AEI was then computed on each htSNP site and averaged across each gene. On average ~2 htSNPs were available to calculate AEI per gene ( Supplementary Fig. 1a ).
To assess overall AEI distribution, we pooled AEI values from all genes. We observed a clear positive skew in normal (2.3) and tumor (1.8) samples, and a bimodal pattern with a main peak at AEI of 0.55 and a small but distinct peak at AEI of 1, indicating the majority of gene-sample pairs show a limited deviation from allelic expression balance while a small proportion represent extreme AEI (Supplementary Figs 1b,c) . The samples were then clustered into homozygous and heterozygous classes for each CCV to test the association between AEIs and CCV genotypes. Using data from the normal samples, we were able to test 705 genes for association with CCV genotypes, representing 820 testable signal-gene pairs. The minimum p-value from CCVs within each signal was used to represent association between that signal and the corresponding gene. In general, we observed stronger association between signals and corresponding genes when they were located closer in the genome (P=7.7e-03; Supplementary Fig. 1d ), consistent with regulatory variants more commonly acting in cis. Overall, in the normal breast samples, 133 genes showed evidence of AEI in heterozygous individuals (P<0.05; Supplementary Table 1) , of which 14 genes passed multiple testing correction (q-value<0.01; Fig. 1 and Table 1 ). Conversely, analysis of the breast tumor samples resulted in 753 testable signal-gene pairs (651 genes) including 84 genes with evidence of AEI in heterozygotes (P<0.05; Supplementary Table 2) , of which two genes passed multiple testing correction (q-value<0.01; Fig. 1 and Table 1 ).
Each of the 16 genes identified by the AEI analyses had multiple tested htSNPs. Therefore, we assessed whether their AEI measurements were consistent across intra-htSNPs. Fourteen genes (BARX2, CASP8, CRLF3, GATAD2A, HSPA4, KLHDC7A, LGR6, NTN4, PPFIA1, RAD23B, STK38L, TMEM80, ZC3H11A and ZNF500) showed consistent AEI across individual htSNPs ( Supplementary Fig. 2a,b, Supplementary Table 3 ). For each gene, only a small number of samples (<10%) had heterogeneous AEIs across individual htSNPs (Pheterogeneity<0.05). However, for Red dots indicate corresponding measurements from TCGA breast tumor datasets. Black dots and whiskers represent means ± 1 SD. P-values were calculated by comparing AEIs between heterozygous and homozygous groups using a two-tailed t-test adjusted for variance.
HLA-A and RPS23, the majority of samples showed heterogeneous AEIs (92% and 71%, respectively) and were therefore excluded from further analysis. It is possible that isoform-specific AEI may have contributed to the heterogeneity of AEI measurements across these two genes.
Breast cancer CCVs distally regulate the AEI gene, NTN4
At six AEI-identified genes (CASP8, GATAD2A, HSPA4, KLHDC7A, LGR6 and ZC3H11A), breast cancer CCVs are located in the promoter regions, suggesting the CCVs may confer allelic imbalance through altered promoter activity. Moreover, for six genes (BARX2, GATAD2A, HSPA4, LGR6, NTN4 and ZC3H11A), our recent capture Hi-C data has indicated that chromatin looping occurs between a region containing the breast cancer CCVs and the promoter of the corresponding gene 11 .
Notably, for GATAD2A, HSPA4 and ZC3H11A, there are CCVs in the promoter and in distal interacting regions, and therefore it would be difficult to determine the CCVs responsible for the observed AEI. One example of a distal CCV associated with AEI is at chromosome 12q22, where genetic fine-mapping identified one risk signal that contains two CCVs (rs61938093 and rs17356097). Both CCVs fall within a putative regulatory element (PRE), marked by open chromatin, which frequently participates in long-range chromatin interactions with the NTN4 promoter region in B80T5 and MCF10A nontumorigenic breast cell lines ( Fig. 2a) . Silencing of the PRE by targeting a nuclease-defective dCas9 fused to the Kruppel-associated box (dCas9-KRAB) reduced NTN4 expression in B80hTERT1 cells, suggesting that the PRE acts as an enhancer (Fig. 2b) . Luciferase reporter assays further confirmed strong enhancer activity of the PRE on the NTN4 promoter.
However, inclusion of the risk-associated CCV alleles did not alter enhancer activity ( Fig. 2c) .
Notably, in T47D, a breast cancer cell line heterozygous for the CCVs, allele-specific 3C showed a preference for the protective allele (Figs 2d,e, Supplementary Fig. 3a,b ), suggesting that risk alleles may abrogate looping between the enhancer and NTN4 which in turn may reduce NTN4 expression. Using electromobility shift assays (EMSAs) we showed that rs61938093 altered protein binding in vitro, suggesting this is the likely functional variant at the signal (Fig. 2f) . However, we were unable to identify the specific protein that binds the risk allele.
NTN4 knockdown increases cell proliferation in vitro and tumor growth in mice
We examined expression of NTN4 in normal and cancerous breast tissues using TCGA RNA-seq data. NTN4 was more highly expressed in normal tissue compared to adjacent tumor samples ( Fig.   3a ) and expressed across the histological subtypes, albeit with lower expression in the basal subtype PCR product that showed allele specific looping at rs61938093. One of three independent 3C libraries is shown. (f) EMSA for oligonucleotide duplexes containing SNPs rs61938093 or rs1735097 with either the risk allele (R) or protective allele (P) as indicated, assayed using B80hTERT1 nuclear extracts. Arrowhead indicates band mobility differences between alleles.
( Fig. 3b) . To assess the effect of reduced NTN4 on cell proliferation, we knocked down NTN4 using siRNA and showed that reduced NTN4 significantly increased cell proliferation ( Fig. 3c,   Supplementary Fig. 3c) . To assess the effect of reduced NTN4 on tumor growth, we stably depleted NTN4 in MCF7 cells by targeting dCAS9-KRAB to the promoter of NTN4, and injected the cells in the mammary fat pad of nude mice. Compared to control MCF7 cells containing non-targeting sgRNA, NTN4 depletion led to a marked increase in tumor growth (Figs 3d,e, Supplementary Fig.   3d ), which was reflected in increased tumor weight ( Fig. 3f ).
DISCUSSION
Identifying the target genes of GWAS variants is challenging and requires multiple bioinformatic and functional approaches. In this study, we used AEI analyses to link breast cancer CCVs to their likely target genes. Using RNA-seq data and imputed genotypes from two breast datasets (TCGA and GTEx), we identified 14 genes in which AEI was associated with breast cancer CCVs at a strict multiple testing threshold. Thirteen genes were identified from 127 normal breast samples and one gene from 669 breast tumor samples. The low number of genes identified from the tumor dataset likely reflects the heterogeneous nature of tumor samples and/or high levels of AEI caused by cancer related mechanisms such as copy number variation, aberrant DNA methylation or acquired regulatory mutations 12 .
We used MTAF as a measure of AEI for each htSNP. This allowed us to average AEIs over multi-htSNP genes (more than 50% of the tested genes) and reduced the influence of sequencing errors at individual htSNPs. Furthermore, we could pool two classes of homozygous genotypes, providing greater statistical power when comparing to heterozygotes. We also retrieved SNP genotypes from high-confidence SNP array calls imputed to the 1000 Genome reference panel and therefore did not rely on setting a minimum cut-off for MTAF when deriving genotypes from RNA-seq data. However, while powerful, we acknowledge this AEI-based approach has some limitations. The multi-level criteria we applied including the minimum expression level or stringent significance threshold may have compromised sensitivity when genes are lowly expressed or only weakly regulated by CCVs. False positives may also arise from htSNP-related mapping biases, caused by repeat sequences or low-complexity regions. In addition, sequencing reads containing the reference allele at a htSNP site are more likely to be mapped, which would result in a false AEI 13, 14 .
Five of the genes we identified have previously been identified through eQTL studies using either breast tumor or normal breast tissue, namely GATAD2A, CASP8, NTN4, HSPA4 and RPS23 15 , while KLHDC7A was previously identified through a transcription wide association study using expression data from breast tissue 16 . In addition, several AEI-identified genes have previously been implicated in cancer biology. CASP8 encodes an apoptotic enzyme that functions as an initiator caspase in the extrinsic apoptotic signalling pathway 17 . CASP8 deficiency can contribute to cancer development through multiple processes, including effects on cellular transformation, adhesion and migration 18, 19 .
BARX2 encodes a homeobox transcription factor that can function as a tumor suppressor and its down regulation is a predictor of poor prognosis in different cancer types [20] [21] [22] . BARX2 can bind the estrogen receptor (the target of tamoxifen) and influence estrogen-dependent growth and cellular invasion 23 . Overexpression of PPFIA1 has also been reported as a potential predictor of metastatic relapse and poor prognosis in estrogen receptor positive/nodal negative breast tumors 24 .
LGR6 is reported to promote cancer development and, when suppressed, induces apoptosis 25 . Moreover, the protein encoded by LGR6 has been specifically detected on the surface of progenitor cells that likely give rise to luminal-type mammary tumors 26 .
Of particular interest was NTN4, which encodes the Netrin-4 secreted protein, implicated in various developmental processes including axon guidance, angiogenesis, and mammary and lung morphogenesis 27 . Several studies have implicated NTN4 in breast cancer progression. For example, reduced NTN4 is reported to promote proliferation, migration and invasion of breast cancer cells by promoting epithelial to mesenchymal transition 28 . In addition, NTN4 has been shown to be an independent biomarker for prognosis of survival in breast cancer 29, 30 . We and others have demonstrated that SNPs can alter chromatin loop formation between promoters and enhancers 31, 32 .
Here, we provide evidence that the same mechanism may explain how breast cancer CCVs alter NTN4 expression and that suppressed NTN4 increases cancer-related processes including cell proliferation and tumor growth.
In summary, we present the most comprehensive AEI analysis linking breast cancer CCVs to their target genes. Fourteen genes were identified, including some potential cancer driver genes, but many with no reported role in breast cancer biology. Future work will be required to confirm the role of these genes in breast cancer development, which could ultimately lead to new avenues for breast cancer prevention or therapy.
METHODS
Allelic expression imbalance (AEI) analyses
CCVs associated with breast cancer risk were tested for association with AEI of genes within 1Mb up-and downstream using RNA-seq data and imputed genotypes from The Cancer Genome Atlas (TCGA; https://portal.gdc.cancer.gov/) and The Genotype-Tissue Expression (GTEx; https://dbgap.ncbi.nlm.nih.gov/) breast datasets. TCGA imputation was performed for individuals with European ancestry (N=701) using 1000 Genomes version 5 reference panel and without prephasing. From dbSNP human Build 146 we extracted SNPs located within exonic regions of the target genes and computed RNA-seq read counts on SNP sites for reference and alternative alleles using bam-readcount (https://github.com/genome/bam-readcount). Sequencing reads with base quality < 15 at a position were not considered for allele counting. For each individual and each gene, heterozygote transcribed SNPs (htSNPs) were identified using imputed genotypes and RNA-seq read counts (>15x RNA-seq read depth). For each gene, AEI of the htSNPs were computed and averaged to represent AEI for that gene (ranging from 0.5 to 1). Homogeneity of AEI across individual htSNPs within a gene was assessed using the MBASED R package. For the analysis of tumor samples, those with copy number alteration for a given gene were excluded. For each CCV, samples were classified into homozygous and heterozygous groups. CCV-gene pairs with less than five samples in either the homozygous or heterozygous group as well as those with a higher AEI mean in the homozygous group were excluded. AEI was compared between heterozygous (AB) and homozygous (AA+BB) samples using a two-sided t-test adjusted for variance. P significance level was adjusted for multiple testing using the q-value method.
Cell lines
Breast cancer cell lines T47D and MCF7 were maintained in RPMI 1640 medium supplemented with 
Chromosome conformation capture (3C)
3C libraries were generated using HindIII from T47D cells as previously described 33 . 3C interactions were quantified by qPCR using the Rotor-Gene 6000 platform, annealing at 66°C for 30 secs in the presence of 25 µM Syto9 fluorescent dye (Life Technologies). BAC clones were used to create artificial libraries of ligation products to normalize for PCR efficiency. Data were normalized to the signal from the BAC clone library and between replicates by reference to a region within GAPDH. Supplementary Table 4 .
3C primers are listed in
Allele specific 3C
T47D 3C libraries or T47D genomic DNA were amplified with allele specific PCR primers ( Supplementary Table 4 ). PCR products were electrophoresed through 2% (w/v) agarose and bands excised for DNA extraction (QIAGEN). Purified amplicons were Sanger sequenced by the Australian Genome Research Facility (AGRF).
Luciferase reporter assays
The NTN4 promoter-driven luciferase reporter construct was generated by inserting a PCR amplified genomic fragment into the KpnI/HindIII sites of the pGL3-basic vector (Promega). A 1999bp fragment containing the PRE, with either the risk or protective alleles, were synthesized as gBlocks (Integrated DNA Technologies) and then cloned into the BamHI/SalI sites of the NTN4-promoter construct (genomic coordinates and primers are listed in Supplementary Table 4 ). B80hTERT1 cells were transfected with the reporter constructs and a control pRL-TK Renilla plasmid using Lipofectamine 3000 (Life Technologies). Luciferase activity was measured 24 h post-transfection using the Dual-Glo Luciferase System (Promega). To correct for any differences in transfection efficiency, Firefly luciferase activity was normalized to Renilla luciferase and the results expressed relative to the NTN4-promoter construct, which had a defined activity of 1. P-values were determined by two-way ANOVA followed by Dunnett's multiple comparisons test.
Electromobility shift assays
Nuclear lysates from B80hTERT1 cells were prepared using the NE-PER nuclear and cytoplasmic protein extraction kit (Thermo Fisher). Biotinylated oligonucleotides representing either the risk or protective allele were synthesized (Integrated DNA Technologies; Supplementary Table 4 ) and annealed to form double-stranded duplexes. Nuclear lysates (5 µg) and duplexes (10 fmol 
RNA interference (RNAi)
MCF7 cells were transfected with either ON-TARGETplus negative control or NTN4 siRNA Table 4 ) using RNAiMAX transfection reagent (Life Technologies) at a concentration of 5 pmol per 10 6 cells. Knockdown of NTN4 was confirmed by TaqMan qPCR gene expression assay 72 h post-transfection.
Smartpools (Dharmacon; Supplementary
Cell proliferation assay
The IncuCyte live cell imaging platform (Essen Bioscience) was used to measure cell proliferation by time course. Treated cells were plated at low confluency and imaged at 10× magnification every 3 h over 7 d. The rate of change of cell confluency was determined using ZOOM 2016A (Essen Bioscience) and Prism (GraphPad) software and compared to control treated cells.
Mouse xenografts
Female BALB/c-Foxn1 nu /Arc mice were subcutaneously implanted with 17β-estradiol (720 µg, 90 d release; Innovative Research of America) at 8 weeks. MCF7 control-CRISPRi or NTN4-CRISPRi cells were orthotopically injected into mammary fatpads 3 days later at 10 
